Therapeutic vaccine BRII-179 restores HBV-specific immune responses in patients with chronic HBV in a phase Ib/IIa study

•BRII-179 admixed with or without IFN-α is safe and well tolerated.•BRII-179 can induce antigen-specific humoral and T-cell responses in patients with CHB.•BRII-179-induced immune responses were insufficient to reduce serum HBsAg in virally suppressed patients.•These data support the further clinical evaluation of BRII-179, especially in combination with other therapies.